Table 3.

Rosuvastatin Use in PCOS

Author/Year	N (M +/- SD)/ Study design/ Duration	Meds Used	Cholesterol Outcomes	Other Findings	Labs
Ghazeeri G, et al.26 (2015)	37 PCOS women (rosuvastatin group: 25.9 +/- 6.5; rosuvastatin + metformin group: 25.7 +/- 5.4), prospective randomized double-blind placebo controlled, 6 month study	Rosuvastatin 10mg/day x 3 mos. Then rosuvastatin + metformin (Rosuvatatin+Metformin) 850mg/BID vs. Rosuvstatin + placebo x 3 months	-TC increased by 14% in Rosuvastatin+Metformin vs. 6% in Rosuvastatin (p = 0.005) LDL increased by 21% in Rosuvastatin+Metformin group vs. 11% in Rosuvastatin (p = 0.007) -No significant changes in HDL or TG	-No significant differences between intervention and control groups were found for CRP, homocysteine, DHEAS, testosterone and insulin -Fasting blood glucose levels increased by 5% vs. 1% (p = 0.02)	Homocysteine levels, testosterone, CRP, DHEAS, FBS, insulin, TC, HDL, LDL, TG

CRP, C reactive protein); DHEAS, dehydroepiandrosterone sulfates; FBS, fasting blood sugar; M, mean; PCOS, Polycystic Ovary Syndrome; HDL, high density lipoprotein; LDL, low density lipoprotein; LH, luteinizing hormone; TC, total cholesterol; TG, triglyceride.